Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

54.17USD
29 Aug 2014
Price Change (% chg)

$0.23 (+0.43%)
Prev Close
$53.94
Open
$54.22
Day's High
$54.45
Day's Low
$53.99
Volume
13,954
Avg. Vol
391,417
52-wk High
$70.71
52-wk Low
$33.05

INCY.OQ

Chart for INCY.OQ

About

Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company’s compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the... (more)

Overall

Beta: 1.19
Market Cap (Mil.): $9,084.14
Shares Outstanding (Mil.): 168.41
Dividend: --
Yield (%): --

Financials

  INCY.OQ Industry Sector
P/E (TTM): -- 154.38 33.56
EPS (TTM): -0.83 -- --
ROI: -34.03 -3.22 17.31
ROE: -- -7.68 18.05
Search Stocks

AstraZeneca and Incyte to study cancer drugs together

LONDON, May 14 - AstraZeneca has signed a clinical study collaboration with U.S. biotech company Incyte , highlighting its desire to push ahead with drug development despite an unwanted $106 billion bid approach from Pfizer.

14 May 2014

Competitors

  Price Change
Pfizer Inc. (PFE.N) $29.42 +0.04
Abbott Laboratories (ABT.N) $42.15 -0.20
Amgen, Inc. (AMGN.OQ) $138.83 +0.14
Biogen Idec Inc (BIIB.OQ) $340.02 -1.22
Array Biopharma Inc (ARRY.OQ) $3.90 +0.03

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks